Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
The Company held an annual meeting of stockholders on December
22, 2016 (the Annual Meeting). At the Annual Meeting, the
stockholders voted on two matters: the re-election of Dr. Alton
L. Boynton and Mr. Cofer Black as Class I members of the Board of
Directors, and ratification of the appointment of Marcum LLP as
the Companys auditors for 2017.
Proposal No. 1. Election of Directors.
The stockholders approved the re-election of Dr. Alton L. Boynton
and Mr. Cofer Black as Class I members of the Board of Directors
to serve until the third annual meeting of stockholders following
the Annual Meeting. Each Class I member was elected at the Annual
Meeting as follows:
| For | Withheld | Broker Non-Votes | |||||||||
| Alton L. Boynton | 29,775,666 | 25,353,676 | 42,340,814 | ||||||||
| Cofer Black | 54,894,381 | 234,961 | 42,340,814 | ||||||||
Proposal No. 2. Ratification of Appointment of Registered
Public Accounting Firm.
The stockholders ratified the appointment of Marcum LLP as the
Companys independent registered public accounting firm for the
year ending December 31, 2017. Proposal No. 2 was approved at the
Annual Meeting as follows:
| For | Against | Abstained | |||||||||
| Ratification of Marcum LLP | 71,364,812 | 559,941 | 25,545,403 | ||||||||
Item 8.01. Other Events.
The Company entered into a $10 million registered direct offering
with certain institutional investors, which offering closed on
December 22, 2016 (the Offering). to the Offering, the Company
sold and issued 28,750,000 shares of common stock and five-year
warrants for the purchase of 14,287,500 shares of common stock at
an exercise price of $0.35. The Company received aggregate
proceeds from the Offering before expenses of approximately $9.2
million.
Also on December 22, 2016, the Company entered into a registered
direct offering with one of its directors, Jerry Jasinowski. to
such offering, Mr. Jasinowki agreed to purchase, subject to
customary closing conditions, 1,285,714 shares of common stock
and five-year warrants for the purchase of 642,857 shares of
common stock at an exercise price of $0.35. The Company will
receive aggregate proceeds from this offering of $450,000.
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer. Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Recent Trading Information
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) closed its last trading session 00.000 at 0.346 with 1,214,526 shares trading hands.